Detalhe da pesquisa
1.
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.
Mod Pathol
; 37(7): 100497, 2024 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38641322
2.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35405088
3.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36056374
4.
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer
; 126(12): 1715-1724, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35194193
5.
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Mod Pathol
; 35(12): 1804-1811, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35842479
6.
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Breast Cancer Res
; 23(1): 36, 2021 03 18.
Artigo
Inglês
| MEDLINE | ID: mdl-33736679
7.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer
; 148(10): 2614-2627, 2021 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33533487
8.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res
; 22(1): 47, 2020 05 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32408905
9.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31162838
10.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32780421
11.
ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Genes Chromosomes Cancer
; 58(3): 175-185, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30520184
12.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
N Engl J Med
; 375(8): 717-29, 2016 Aug 25.
Artigo
Inglês
| MEDLINE | ID: mdl-27557300
13.
Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Breast Cancer Res Treat
; 173(2): 429-438, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30315437
14.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30632020
15.
Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Ann Surg Oncol
; 26(8): 2435-2443, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31049766
16.
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2ß.
Lab Invest
; 98(1): 117-129, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29035379
17.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28664507
18.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Int J Cancer
; 139(4): 882-9, 2016 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26946057
19.
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.
Proc Natl Acad Sci U S A
; 110(41): 16580-5, 2013 Oct 08.
Artigo
Inglês
| MEDLINE | ID: mdl-24065821
20.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Breast Cancer Res Treat
; 150(2): 279-88, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25721604